Biotechnology
Akeso Publishes Preclinical Results of TIGIT monoclonal antibody（AK127）at the American Association for Cancer Research (AACR) 2022 Annual Meeting
HONG KONG, April 14, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ( "Akeso" ), a China-based biopharmaceutical company focusing on the development and commercialization of innovative therapeutic antibodies for Oncology & Immunology, announced the publication of preclinical results of its anti-TIGIT...
2022-04-14 14:54
1415
Toyobo launches major marketing initiative for Nerbridge(TM) in the U.S., setting sights on the global nerve conduit market
OSAKA, Japan, April 13, 2022 /PRNewswire/ -- Toyobo Co., Ltd. has launched a major U.S. marketing initiative for NerbridgeTM ("the product", hereafter), a conduit for peripheral nerve regeneration. On January 11, 2022, Toyobo kicked off the sales promotion campaign at a conference jointly held i...
2022-04-14 10:03
1263
InxMed FAK Inhibitor IN10018 Received Breakthrough Therapy Designation by the China National Medical Products Administration for Platinum-Resistant Ovarian Cancer
NANJING, China, April 13, 2022 /PRNewswire/ -- InxMed Co., Ltd. announced that IN0018, its focal adhesion kinase (FAK) inhibitor, had been granted with Breakthrough Therapy Designation by the China National Medical Products Administration. This designation is based on the results of a Phase Ib...
2022-04-14 08:00
1829
Origin Agritech to Host First Half 2022 Earning Conference Call
BEIJING, April 13, 2022 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), an agriculture technology company, today announced that it will file its first half 2022 financial results onThursday, May 5, 2022 before the market open and will host a conference call that s...
2022-04-14 02:51
1803
Insilico Medicine Announces Advancement of Its Preclinical Candidate for USP1 Synthetic Lethality Target to IND-enabling Studies for Various Oncological Disorders
Insilico Medicine Nominates Its USP1 Small Molecule Inhibitor as a Preclinical Candidate for Tumors with Homologous Recombination Deficiency NEW YORK, April 13, 2022 /PRNewswire/ -- Insilico Medicine ("Insilico"), a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery com...
2022-04-13 23:00
2755
European Wellness Signs MOU in Dubai Expo 2020 to Strengthen Medical Tourism into Malaysia and Develop Advanced Biological Regenerative Medicine in UAE
DUBAI, UAE, April 13, 2022 /PRNewswire/ -- European Wellness Biomedical Group (EW Group), through its Malaysian subsidiary European Wellness Academie, and Dubai- based healthcare distribution and technology group, AK International LLC, have signed a Memorandum of Understanding (MOU) on 30th March ...
2022-04-13 21:38
2811
Happiness Development Donated Anti-epidemic Materials to Minhang District, Shanghai
NANPING, China, April 13, 2022 /PRNewswire/ -- Happiness Development Group Limited ("HAPP" or the "Company"), (NASDAQ: HAPP) an emerging and diversified company engaging in the business of production and sale of nutraceutical and dietary supplements, providing e-commerce sales and marketing solu...
2022-04-13 20:00
1902
HanAll Biopharma and Daewoong Pharmaceutical Invest in Turn Biotechnologies to Expand Growth Initiative
* HanAll Biopharma and Daewoong Pharmaceutical invest in the broad potential of Turn Biotechnologies * Turn has developed a novel cell rejuvenating platform with significant potential for application in an array of age-related diseases SEOUL, South Korea ,April 12, 2022 /PRNewswire/ -- HanAll...
2022-04-13 08:00
1212
JUNIPER BIOLOGICS ACQUIRES CELL-MEDIATED GENE THERAPY TG-C LD FOR TREATMENT OF KNEE OSTEOARTHRITIS
$600 million USD acquisition will see Juniper Biologics offer the world's first cell-mediated gene therapy to an estimated 300 million patients inAsia Pacific, Middle East and Africa SINGAPORE, April 13, 2022 /PRNewswire/ -- Juniper Biologics, a science-led healthcare company focused on researc...
2022-04-13 07:57
1635
Bridge Biotherapeutics Presented the Preclinical Data of BBT-207 at the AACR Annual Meeting 2022
* The preclinical data supports the clinical development of BBT-207 for EGFR mutant NSCLC patients harboring C797S double mutations, as well as for those who are treatment-naïve * The company plans to submit an IND application to the US FDA in 2022 and looks forward to entering the Phase 1 st...
2022-04-13 06:00
768
MediLink Therapeutics Receives FDA Clearance of IND Application for YL201 Antibody Drug Conjugate Product
SUZHOU, China, April 12, 2022 /PRNewswire/ -- MediLink Therapeutics announced that YL201, the first compound based on MediLink's proprietary antibody-drug conjugate (ADC) technology platform, has been cleared on its Investigational New Drug (IND) application by the U.S. Food and Drug Administrati...
2022-04-12 20:55
463
Gastrointestinal Biotech Company Renexxion Ireland Announces $100M Investment Commitment
ROSCREA, Ireland, April 12, 2022 /PRNewswire/ -- Renexxion Ireland Ltd., a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need in gastrointestinal ("GI") disorders, announced today that it has entered into a share subscription agreement with...
2022-04-12 20:00
931
New Clinical Advisory Board to support PromarkerD global rollout
* Proteomics International establishes world class Clinical Advisory Board
promarkerd.com/clinical-advisory-board
2022-04-12 16:04
858
Abbott Senior Medical Director joins Nutromics as inaugural Chief Medical Officer
MELBOURNE, Australia, April 12, 2022 /PRNewswire/ -- Australian and US MedTech start-up Nutromics (Nutromics or the Company), a global leader in DNA-based biosensors, today announced that DrAgim Beshiri, most recently Senior Medical Director at Abbott Laboratories, has joined the organisation as ...
2022-04-12 09:28
684
The NDA of Henlius Novel Anti-PD-1 mAb Serplulimab for the First-Line Treatment of Small Cell Lung Cancer Accepted by NMPA
SHANGHAI, April 11, 2022 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the New Drug Application (NDA) of HANSIZHUANG (serplulimab), a novel anti-PD-1 monoclonal antibody (mAb) independently developed by the company, in combination with chemotherapy for the first-line tr...
2022-04-11 22:07
1412
PharmAbcine Presents Updated Preclinical Data of Its Anti-VISTA Antibody Candidate at AACR 2022
DAEJEON, South Korea, April 11, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), aclinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the Company presented an updated preclinical data PMC-309, the Company's anti-VISTA ...
2022-04-11 20:00
593
Global pharma organizations back Turn Biotechnologies to advance its cell rejuvenation program
Daewoong Pharmaceutical, HanAll Biopharma join Astellas Venture Management and other VCs in oversubscribed funding round to accelerate Turn Bio's preclinical advances in multiple therapeutic areas MOUNTAIN VIEW, Calif., April 11, 2022 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation com...
2022-04-11 19:00
1143
APRINOIA Therapeutics received FDA clearance to initiate APNmAb005 Phase 1 clinical trial
BOSTON, April 11, 2022 /PRNewswire/ -- APRINOIA Therapeutics announces today that the U.S. Food and Drug Administration (FDA) has granted a may proceed authorization for its novel therapeutic anti-tau monoclonal antibody, APNmAb005, allowing the company to test and evaluate its safety in healthy ...
2022-04-11 18:00
1206
Frost & Sullivan Hails Sphere Fluidics for Enabling Efficient, Faster, and More Cost-effective Single-cell Analysis with Its Microfluidic Platforms
The flexible and easy-to-use microfluidic platforms easily adapt to customers' unique research needs, boost throughput and efficiency, and enhance customers' single-cell research capabilities. SAN ANTONIO, April 11, 2022 /PRNewswire/ -- Frost & Sullivan recently analyzed the European microfluidi...
2022-04-11 18:00
449
InventisBio Reported Promising Phase I Study Results of a Novel KRAS G12C Inhibitor D-1553 in Cancer Patients
SHANGHAI, April 11, 2022 /PRNewswire/ -- InventisBio Co., Ltd., a clinical-stage biotech company based inShanghai, China has published the clinical data of their oral KRAS G12C inhibitor D-1553, for the first time in cancer patients. These data are presented in two e-posters at the annual meetin...
2022-04-11 17:37
471
Week's Top Stories
Most Reposted
Multiple achievements made in China-Hungary BRI conference
[Picked up by 319 media titles]
2024-05-03 06:59
Shanghai Jiao Tong University Offers Free Online Courses for International Learners, Joint Programs with Tmall of Alibaba and Dow Gain High Popularity
[Picked up by 317 media titles]
2024-05-07 08:00
VentureBlick Launches 'Discovery': The First Global Networking Platform for Healthcare Innovation
[Picked up by 312 media titles]
2024-05-08 14:37
OPTIX raises US$15 million fundraising to date to solve the bottleneck of XR optics technology
[Picked up by 306 media titles]
2024-05-08 08:00IN2MF in Kuala Lumpur Presented by Bank Indonesia
[Picked up by 290 media titles]
2024-05-08 16:44
Most Read
/C O R R E C T I O N -- Addverb/
2024-05-03 20:26
14378
Multiple achievements made in China-Hungary BRI conference
2024-05-03 06:59
9999
Xinhua president, Hungarian economy minister vow to bolster media cooperation
2024-05-03 06:25
9532
